Optinose Shares Surge Premarket on Takeover Deal With Paratek

Dow Jones

Mar 20, 2025

By Colin Kellaher

Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million.

Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company.

Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share.

Optinose shares were recently up 59% to $9.56 in premarket trading.

The deal is slated to close as early as mid-2025.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 20, 2025 05:59 ET (09:59 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520143911"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520143911\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520143911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 17:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520143911","market":"hk","top_or_hot":-1,"title":"Optinose Shares Surge Premarket on Takeover Deal With Paratek","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million. \n</p>\n<p>\n  Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company. \n</p>\n<p>\n  Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share. \n</p>\n<p>\n  Optinose shares were recently up 59% to $9.56 in premarket trading. \n</p>\n<p>\n  The deal is slated to close as early as mid-2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optinose Shares Surge Premarket on Takeover Deal With Paratek</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptinose Shares Surge Premarket on Takeover Deal With Paratek\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-20 17:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million. \n</p>\n<p>\n  Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company. \n</p>\n<p>\n  Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share. \n</p>\n<p>\n  Optinose shares were recently up 59% to $9.56 in premarket trading. \n</p>\n<p>\n  The deal is slated to close as early as mid-2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPTN","symbol_name":"Optinose Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520143911","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520143911","pubTimestamp":1742464740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million.Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company.Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share.Optinose shares were recently up 59% to $9.56 in premarket trading.The deal is slated to close as early as mid-2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPTN":"Optinose Inc.","BK4007":"制药"},"translate_title":"Optinose股价因与Paratek达成收购协议而盘前飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPTN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million. \n\n\n  Paratek late Wednesday said it will pay an initial $9 a share in cash for Optinose, a 50% premium to Wednesday's closing price of $6 for the Yardley, Pa., company. \n\n\n  Optinose shareholders also will receive contingent value rights worth up to $5 a share tied to future sales of the chronic rhinosinusitis treatment Xhance, bringing the total potential deal value to $14 a share. \n\n\n  Optinose shares were recently up 59% to $9.56 in premarket trading. \n\n\n  The deal is slated to close as early as mid-2025. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 05:59 ET (09:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}